We are the combination of four hospitals: the General Hospital, the Children’s Hospital, the Women’s Hospital and the Traumatology, Rehabilitation and Burns Hospital. We are part of the Vall d’Hebron Barcelona Hospital Campus: a world-leading health park where healthcare plays a crucial role.
Below we will list the departments and units that form part of Vall d’Hebron Hospital and the main diseases that we treat. We will also make recommendations based on advice backed up by scientific evidence that has been shown to be effective in guaranteeing well-being and quality of life.
Would you like to know what your stay at Vall d'Hebron will be like? Here you will find all the information.
The commitment of Vall d'Hebron University Hospital to innovation allows us to be at the forefront of medicine, providing first class care adapted to the changing needs of each patient.
Speaker: Prof. Takeaki Ishizawa, M.D., Ph.D., F.A.C.S. - Department of Hepatobiliary-Pancreatic Surgery, Graduate School of Medicine, Osaka Metropolitan University.
Abstract: Intraoperative fluorescence imaging using indocyanine green (ICG) has become used widely for real-time visualization of biological structures and assessment of blood perfusion. I herein demonstrate development history and clinical applications of ICG-fluorescence imaging to HBP surgery. 1) Fluorescence cholangiography: fluorescence images of the extrahepatic bile ducts can be obtained by intrabiliary injection of ICG solution (0.025 mg/mL) or preoperative intravenous injection (IV) of ICG (2.5 mg). The latter technique begins to be used worldwide for confirmation of the bile duct anatomy during minimally-invasive cholecystectomy. 2) Identification of hepatic tumors: IV-injected ICG (0.5 mg/kg) accumulates in hepatocellular carcinoma tissues and in non-cancerous hepatic parenchyma surrounding liver metastasis, which can be used for intraoperative identification of subcapsular hepatic tumors by fluorescence imaging. 3) Hepatic segmentation: ICG solution (0.25 mg in 5 mL indigo-carmine solution) is injected into a tumor-bearing portal branch under ultrasound guidance (positive staining technique). ICG can also be administered intravenously following closure of a corresponding portal pedicle (negative staining technique). These techniques enable long-lasting delineations of segmental boundaries throughout hepatectomy procedures because ICG retains in hepatocytes for more than 5 hours. 4) Assessment of blood perfusion: fluorescence imaging following intraoperative bolus IV ICG (2.5mg) visualizes arterial/portal blood flows and perfusions to the surrounding organs during surgeries with resection/reconstruction of major vessels. Along with current dissemination of ICG-fluorescence imaging, novel target-specific fluorophores and imaging devices are being developed actively. Our approach is to use enzyme-activatable fluorophores for real-time visualization of cancerous tissues and leaking pancreatic juice. The fluorescence imaging techniques will develop into an indispensable intraoperative navigation tool, enhancing safety and curability of HBP surgery.
Host:
Dr. Itxarone Bilbao, Hepatobiliopancreatic surgery and transplants, Children's Hospital and Woman's Hospital.
Dr. Concepción Gómez, Main researcher -Hepato-bilio-pancreatic surgery (HBP) and liver transplantation.
By accepting these conditions, you are agreeing to the processing of your personal data for the provision of the services requested through this portal, and, if necessary, for any procedures required by the administrations or public bodies involved in this processing, and their subsequent inclusion in the aforementioned automated file. You may exercise your rights to access, rectification, cancellation or opposition by writing to web@vallhebron.cat, clearly stating the subject as "Exercising of Data Protection Rights". Operated by: Hospital Universitari Vall d'Hebron - Institut Català de la Salut. Purpose: Manage the user’s contact information. Legitimisation: Express acceptance of the privacy policy. Rights: To access, rectify, and delete personal information data, as well to the portability thereof and to limit and/or oppose their use. Source: The interested party themselves.